The 2026 multisociety guideline from the American Society of Regional Anesthesia and Pain Medicine, American Academy of Pain Medicine, American Society of Interventional Pain Physicians, and International Pain and Spine Intervention Society states that there is limited evidence to guide selection of one intra-articular corticosteroid over another. The most commonly used preparations were methylprednisolone acetate, triamcinolone hexacetonide, and triamcinolone acetonide, and the guideline concluded that different preparations appear to have similar effectiveness but may differ in duration of action; evidence was insufficient to recommend one preparation over another. Comparative evidence included methylprednisolone acetate and triamcinolone acetonide at 20- and 40-mg doses for shoulder injections, with no differences in pain or function among preparations or doses, while 40 mg of either triamcinolone or methylprednisolone was described as commonly used for hip intra-articular injections. Extended-release triamcinolone acetonide 32 mg was also compared with conventional triamcinolone acetonide 40 mg for knee injections and was not significantly different for the primary pain outcome. Overall, the guideline describes methylprednisolone acetate and triamcinolone hexacetonide as other commonly used intra-articular corticosteroids, but available evidence does not establish a specific corticosteroid or dose as an equivalent substitute for triamcinolone acetonide 40 mg/mL. [1]
The 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends intra-articular glucocorticoid injections for knee and hip osteoarthritis and conditionally recommends them for hand osteoarthritis, with evidence supporting short-term efficacy in knee osteoarthritis. However, the guideline does not identify specific corticosteroid preparations or doses as preferred alternatives to triamcinolone 40 mg/mL. Available evidence was considered insufficient to determine whether short- versus long-acting corticosteroid preparations or lower versus higher doses should be preferred. Thus, although the guideline supports intra-articular glucocorticoids as a treatment option, it does not provide specific guidance for selecting another corticosteroid or dose in place of triamcinolone 40 mg/mL. [2]
A 2019 review of intra-articular treatments for knee osteoarthritis described intra-articular glucocorticoids as an established treatment option for short-term symptom relief, although recommendations and estimates of benefit varied across guidelines and systematic reviews. The authors noted that the American Academy of Orthopaedic Surgeons considered the evidence inconclusive, whereas the Osteoarthritis Research Society International considered intra-articular glucocorticoids appropriate; National Institute for Health and Care Excellence guidance supported their use for short-term (1-4 week) pain relief, and an updated Cochrane meta-analysis suggested small-to-moderate benefit over placebo for up to 6 weeks, with uncertainty regarding clinical importance and substantial variability across trials. The authors also highlighted potential safety concerns with repeated treatment, including greater cartilage volume loss reported over 2 years with intra-articular triamcinolone 40 mg compared with saline. Regarding alternative formulations, extended-release triamcinolone acetonide (Zilretta 32 mg) was designed to prolong intra-articular exposure, but its clinical advantage over conventional triamcinolone acetonide was considered unclear because a phase III trial did not demonstrate significant improvement in the primary pain outcome versus conventional triamcinolone. Overall, while the review discussed glucocorticoids broadly and specifically evaluated conventional and extended-release triamcinolone, it did not describe use of other corticosteroid preparations. [3]
Lastly, a 2024 systematic review and meta-analysis evaluated 18 randomized controlled trials, including 16 human studies with 1,577 patients, comparing different intra-articular corticosteroid preparations and doses for osteoarthritis, predominantly of the knee. The corticosteroids evaluated in human studies included triamcinolone, methylprednisolone acetate, betamethasone, and dexamethasone palmitate. Relevant to triamcinolone acetonide 40 mg, one study directly compared triamcinolone acetonide 40 mg with methylprednisolone acetate 40 mg and betamethasone disodium phosphate 3 mg, with methylprednisolone providing greater pain relief through 6 weeks; additional studies comparing methylprednisolone acetate 40 mg with triamcinolone hexacetonide 20 or 40 mg reported variable results depending on the follow-up period. In the pooled analysis of triamcinolone versus methylprednisolone, triamcinolone was associated with statistically lower post-injection pain scores at ≤2 weeks, although the difference did not meet the prespecified threshold for clinical importance, and no significant differences in pain improvement from baseline were observed between treatments at any follow-up through 24 weeks. Overall, the quality of evidence for the meta-analyzed pain outcomes was rated low, and the authors concluded that available comparative evidence is insufficient to determine an optimal intra-articular corticosteroid preparation or dose. [4]